Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Grenoble
Multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively.
The cohort will include:
* 30 patients PD-L1 \> 50% treated with pembrolizumab in first line and having a progression free survival ≥ 3 months
* 30 patients PD-L1 \> 50% treated with pembrolizumab in first line and having a progression free survival \< 3 months
* 30 patients PD-L1 \< 50% treated with cisplatin-based chemotherapy in first line
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
NSCLC diagnosis
Advanced disease (Stage III-IV) according to the TNM 7th/8th classification
Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or cisplastin-based chemotherapy if PD-L1 \< 50%
FFPE material available from diagnostic sample
You may not be if
\-
Clareo Health | cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
